China Pharmaceutical Industry Report, 2004-2005
  • Jun/2005
  • Hard Copy
  • USD $800
  • Pages:130
  • Single User License
    (PDF Unprintable)       
  • USD $900
  • Code:
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $1,800
  • Hard Copy + Single User License
  • USD $1,000
      

The report sums up the development of the global and Chinese pharmaceutical markets in 2004. Through accurate data and full elaboration, it presents the status, features and competition pattern of China's pharmaceutical market. Meanwhile, it makes a comprehensive evaluation of the operational strategies and competitiveness of key enterprises in the industry.

The report especially points out the following: In 2004, China's pharmaceutical industry continued to maintain a momentum of steady growth, achieving a stable rise in both output and sales revenues. Exports maintained a stable growth and there was a continuous improvement in the industry's international competitiveness. Market competition changed from pure pursuit of market shares to comprehensive competition based on multiple factors. Competition among brands intensified. Among the industry segments, the chemical preparation industry   was in steady growth, while the raw chemical material industry grew slowly. Traditional Chinese medicine was in a stage of combination with modern technologies, while the biopharmaceutical industry was in an early period of growth and was moving towards more R&D activities. 

Based on an in-depth analysis of major factors affecting the development of China's pharmaceutical industry from 2005 to 2009, the report presents qualitative and quantitative forecast of the development trend of the industry. It also evaluates investment values in the industry. Finally, it provides pertinent development strategies and recommendations for the government, enterprise and investors respectively.

 

1.Overview of Development of the Global Pharmaceutical Industry in 2004
1.1 Development Status
1.2 Basic Characteristics
1.3 Overview of Industry Development in Major Countries and Regions 
1.3.1 USA
1.3.2 Europe
1.3.3 Japan
1.3.4 Canada
1.4 Brief Introduction to Key Multinational Enterprises 

2.Overview of Development of China's Pharmaceutical Industry in 2004
2.1 Growth Environment
2.1.1 Policy Environment
2.1.2 Investment Environment
2.1.3 Economic Environment
2.2 Development Status
2.3 Basic Characteristics
2.4 Industry Segments
2.4.1 Chemical Bulk Drug Manufacturing Industry
2.4.2 Traditional Chinese Medicine Manufacturing Industry
2.4.3 Biological Pharmaceutical Manufacturing Industry

3.Competition Situation and Behavior in China's Pharmaceutical Industry in 2004
3.1 Competition Situation
3.1.1 Chemical Bulk Drug Manufacturing Industry
3.1.2 Traditional Chinese Medicine Manufacturing Industry
3.1.3 Biological Pharmaceutical Manufacturing Industry
3.2 Competition Behavior
3.2.1 Chemical Bulk Drug Manufacturing Industry
3.2.2 Traditional Chinese Medicine Manufacturing Industry
3.2.3 Biological Pharmaceutical Manufacturing Industry
3.3 Competition Performance
3.3.1 Chemical Bulk Drug Manufacturing Industry
3.3.2 Traditional Chinese Medicine Manufacturing Industry
3.3.3 Biological Pharmaceutical Manufacturing Industry

4.Evaluation of Competitiveness of Key Enterprises in China's Pharmaceutical Industry in 2004

5.Analysis of Driving Forces for Growth of China's Pharmaceutical Industry, 2005-2009
5.1 Policy Factor
5.2 Technological Factor
5.3 Talent Factor
5.4 Capital Factor
5.5 Economic Factor

6.Analysis of Development Trend of China's Pharmaceutical Industry, 2005-2009
6.1 Trend of Industry Development
6.2 Trend of Competition Development
6.3 Trend of Structural Development

7.Forecast for Development of China's Pharmaceutical Industry, 2005-2009
7.1 Forecast for Industry Size
7.2 Forecast for Market Pattern

8.Analysis of Investment Opportunities in China's Pharmaceutical Industry, 2005-2009
8.1 Evaluation of Investment Values In Industry
8.1.1 Chemical Bulk Drug Manufacturing Industry
8.1.2 Traditional Chinese Medicine Manufacturing Industry
8.1.3 Biological Pharmaceutical Manufacturing Industry
8.2 Analysis of Investment Opportunities
8.2.1 Chemical Bulk Drug Manufacturing Industry
8.2.2 Traditional Chinese Medicine Manufacturing Industry
8.2.3 Biological Pharmaceutical Manufacturing Industry

9.Recommendations

China Contract Research Organization (CRO) Industry Report, 2020-2026

The contract research organization (CRO) industry has been galloping amid the global pharmaceutical market steadily in head way, the vibrant financing in the medical and health sector, and the prolife...

China Human Vaccine Industry Report, 2020-2026

In China, the lot release for human vaccines plunged by 17.7% in 2018 when the production record fraud of rabies vaccines for human use, freeze-dried by Changsheng Bio-Technology was exposed. The impa...

China Pharmaceutical Distribution Industry Report, 2019-2026

The Chinese pharmaceutical distribution market has been expanding steadily over the recent years, being valued at RMB2,330.3 billion in 2019 with a year-on-year increase of 8.9%, of which the pharmace...

China Pharmaceutical Distribution Industry Report, 2019-2025

China’s pharmaceutical distribution industry has sustained steady growth over the years. In 2018, the market was worth RMB2,194.5 billion, a 9.6% rise from RMB2,001.6 billion (up by 8.4% YoY) in 2017,...

China Pharmaceutical Packaging Industry Report, 2019-2025

Being incentivized by the burgeoning pharmaceuticals industry, Chinese pharmaceutical packaging market size sustained growth rates of around 10% in recent years, and outstripped RMB100 billion in 2018...

China Blood Product Industry Report, 2018-2022

The blood product industry in China develops under stimulation of industry policies and downstream demand. The country recorded total lot release volume of 64.11 million bottles of blood products in 2...

China Pharmaceutical Distribution Industry Report, 2017-2021

The Chinese pharmaceutical distribution market has developed steadily but at a slower rate in recent years. The industry rose by 10.4% year on year to RMB1.8393 trillion in 2016 and is expected to hit...

China Blood Product Industry Report, 2017-2021

China’s blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 201...

China Pharmaceutical Packaging Industry Report, 2016-2021

Under the impetus of the fast-growing downstream pharmaceutical industry, Chinese pharmaceutical packaging market size increased year by year at the CAGR of 11.2% during 2010-2016. From 2017 to 2021, ...

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Ch...

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号